The Cancer News
AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Research
The volume and pace of cancer research, from preclinical studies to clinical trials and FDA approvals, can make it challenging to stay informed. This section highlights the latest developments and translates complex scientific concepts into clear, accessible insights for both healthcare professionals and the broader public.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Durvalumab For Muscle-Invasive Bladder Cancer
By The Cancer News Team
FDA approves durvalumab with chemotherapy as neoadjuvant and adjuvant treatment for muscle-invasive bladder cancer, showing improved survival in the NIAGARA trial.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
FDA Approves Cabozantinib for Adults and Pediatric Patients 12 Years of Age and Older With Pancreatic Neuroendocrine Tumors and Extra-Pancreatic Neuroendocrine Tumors
By The Cancer News Team
Cabozantinib receives FDA approval for treating advanced pancreatic and extra-pancreatic neuroendocrine tumors in patients 12 years and older, following positive CABINET trial results.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
The FDA approves a new drug for HER2-positive gastric or gastroesophageal junction adenocarcinoma expressing PD-L1
By The Cancer News Team
The FDA has approved pembrolizumab in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive gastric or GEJ adenocarcinoma expressing PD-L1 (CPS ≥ 1), based on improved survival outcomes in a Phase 3 clinical trial.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
A New Combination in Kidney Cancer Therapy: High Doses of Seleno-L-Methionine and Axitinib in a Phase I Trial
By Dr. Yousef Zakharia
A Phase I trial explores the safety, efficacy, and tumor-suppressing effects of high-dose Seleno-L-Methionine (SLM) with Axitinib in metastatic clear cell renal carcinoma (mccRCC), showing promising early results.
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
FDA Approves Alectinib for Adjuvant Treatment in Non-Small Cell Lung Cancer
By Dr. Anish Shah
By: **Dr. Anish Shah** [Bronx-Lebanon Hospital](https://www.bronxcare.org/); Bronx, NY On April 18, 2024, the U.S. Food and Drug Administration granted approval to a potent oral ALK (anaplastic lym...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
Authors' Take: Consequences of Cancer Diagnosis in India
By Editorial Team
This week, The Cancer News had the opportunity to connect with three authors (Dr. Aju Mathew, Sruti Ranganathan, and Dr. Edward Christopher Dee) of a recent article in the peer-reviewed Journal **Supp...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
ASCO23 - WU-KONG6 Trial Summary
By Editorial Team
**Author:** Lei Deng, MD Roswell Park Comprehensive Cancer Center _**Live report from ASCO23, Chicago, IL**_ June 6, 2023 **[9002](https://meetings.asco.org/abstracts-presentations/220375) Sunvoze...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...
Adjuvant Ribociclib and Endocrine Therapy in Patients with HR+/HER2 Negative Early Breast Cancer: Phase III NATALEE Trial
By Editorial Team
By Dr. Shipra Gandhi from Roswell Park Comprehensive Cancer Center Findings from the MonarchE clinical trial1 led to the approval of combination abemaciclib with AI in the adjuvant setting for pat...